期刊
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
卷 23, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ijms23062960
关键词
metabolism; heart failure; pharmacology
资金
- Natural Sciences and Engineering Research Council of Canada
Cardiovascular disease is the leading cause of mortality globally, with heart failure affecting millions of people. The use of metabolomics and lipidomics has improved our understanding of heart failure and revealed new pathways and potential interventions. The discovery of metabolic effects of heart failure drugs, particularly sodium-glucose transport protein 2 inhibitors, has revolutionized the treatment of heart failure.
Cardiovascular disease is the leading cause of mortality globally with at least 26 million people worldwide living with heart failure (HF). Metabolism has been an active area of investigation in the setting of HF since the heart demands a high rate of ATP turnover to maintain homeostasis. With the advent of -omic technologies, specifically metabolomics and lipidomics, HF pathologies have been better characterized with unbiased and holistic approaches. These techniques have identified novel pathways in our understanding of progression of HF and potential points of intervention. Furthermore, sodium-glucose transport protein 2 inhibitors, a drug that has changed the dogma of HF treatment, has one of the strongest types of evidence for a potential metabolic mechanism of action. This review will highlight cardiac metabolism in both the healthy and failing heart and then discuss the metabolic effects of heart failure drugs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据